[1] Robertson NP. Advances in Tourette′s syndrome[J]. J Neurol, 2023, 270(3): 1808-1810. [2] Yu D, Sul JH, Tsetsos F, et al. Interrogating the genetic determinants of Tourette′s syndrome and other tic disorders through genome-wide association studies[J]. Am J Psychiatry, 2019, 176(3): 217-227. [3] Mahjani B, Bey K, Boberg J, et al. Genetics of obsessive-compulsive disorder[J]. Psychol Med, 2021, 51(13): 2247-2259. [4] Pedersen JH, Skytthe A, Bybjerg-Grauholm J, et al. Concordance and comorbidities among monozygotic twins with tic disorders[J]. J Psychiatr Res, 2022, 146: 297-303. [5] Wang X, Liu X, Chen L, et al. The inflammatory injury in the striatal microglia-dopaminergic-neuron crosstalk involved in Tourette syndrome development[J]. Front Immunol, 2023, 14: 1178113. [6] Israelashvili M, Yael D, Vinner E, et al. Common neuronal mechanisms underlying tics and hyperactivity[J]. Cortex, 2020, 127: 231-247. [7] Schilke E D, Tremolizzo L, Appollonio I, et al. Tics: Neurological disorders determined by a deficit in sensorimotor gating processes[J]. Neurol Sci, 2022, 43(10): 5839-5850. [8] Chen M, Ruan G, Chen L, et al. Neurotransmitter and intestinal interactions: Focus on the microbiota-gut-brain axis in irritable bowel syndrome[J]. Front Endocrinol (Lausanne), 2022, 13: 817100. [9] Peerboom C, Wierenga C J. The postnatal GABA shift: A developmental perspective[J]. Neurosci Biobehav Rev, 2021, 124: 179-192. [10] Luscher B, Maguire J L, Rudolph U, et al. GABA(A) receptors as targets for treating affective and cognitive symptoms of depression[J]. Trends Pharmacol Sci, 2023, 44(9): 586-600. [11] Koh W, Kwak H, Cheong E, et al. GABA tone regulation and its cognitive functions in the brain[J]. Nat Rev Neurosci, 2023, 24(9): 523-539. [12] Sears SM, Hewett SJ. Influence of glutamate and GABA transport on brain excitatory/inhibitory balance[J]. Exp Biol Med (Maywood), 2021, 246(9): 1069-1083. [13] Tanaka K. Astroglia and obsessive compulsive disorder[J]. Adv Neurobiol, 2021, 26: 139-149. [14] Johnson KA, Worbe Y, Foote KD, et al. Tourette syndrome: clinical features, pathophysiology, and treatment[J]. Lancet Neurol, 2023, 22(2): 147-158. [15] Favuzzi E, Huang S, Saldi GA, et al. GABA-receptive microglia selectively sculpt developing inhibitory circuits[J]. Cell, 2021, 184(15): 4048-4063.e32. [16] Cothros N, Medina A, Pringsheim T. Current pharmacotherapy for tic disorders[J]. Expert Opin Pharmacother, 2020, 21(5): 567-580. [17] Shitovaa D, Zharikova TS, Kovaleva ON, et al. Tourette syndrome and obsessive-compulsive disorder: A comprehensive review of structural alterations and neurological mechanisms[J]. Behav Brain Res, 2023, 453: 114606. [18] Israelashvili M, Yael D, Vinner E, et al . Common neuronal mechanisms underlying tics and hyperactivity[J]. Cortex, 2020,127:231-247. [19] Worbe Y, Marrakchi-Kacem L, Lecomte S, et al. Altered structural connectivity of cortico-striato-pallido-thalamic networks in Gilles de la Tourette syndrome[J]. Brain, 2015, 138(Pt 2): 472-482. [20] Lennington JB, Coppola G, Kataoka-Sasaki Y, et al. Transcriptome analysis of the human striatum in Tourette syndrome[J]. Biol Psychiatry, 2016, 79(5): 372-382. [21] Barbour AJ, Gourmaud S, Lancaster E, et al. Seizures exacerbate excitatory: inhibitory imbalance in Alzheimer′s disease and 5XFAD mice[J]. Brain, 2024,147(6):2169-2184. [22] Zhang W, Yu W, Liu X, et al. Effect of Jian-Pi-Zhi-Dong decoction on the amino acid neurotransmitters in a rat model of Tourette syndrome and comorbid anxiety disorder[J]. Front Psychiatry, 2020, 11: 515. [23] Xiao L, Priest MF, Nasenbeny J, et al. Biased oxytocinergic modulation of midbrain dopamine systems[J]. Neuron, 2017, 95(2): 368-384.e5. [24] Cadeddu R, Knutson DE, Mosher LJ, et al. The α6 GABA(A) receptor positive allosteric modulator DK-I-56-1 reduces tic-related behaviors in mouse models of Tourette syndrome[J]. Biomolecules, 2021,11(2):175. [25] Draper A, Stephenson MC, Jackson GM, et al. Increased GABA contributes to enhanced control over motor excitability in Tourette syndrome[J]. Curr Biol, 2014, 24(19): 2343-2347. [26] 于文静,白雪,张雯,等.健脾止动汤对多发性抽动症患儿神经递质的影响[J].中华中医药杂志,2015,30(5):1757-1761. Yu WJ, Bai X, Zhang W, et al. Effect of spleen-enhancing and stopping action soup on neurotransmitters in children with multiple tic disorders[J]. Chinese Medicine Miscellany, 2015,30(5):1757-1761.(in Chinese) [27] Liu S, Tian M, He F, et al. Mutations in ASH1L confer susceptibility to Tourette syndrome[J]. Mol Psychiatry, 2020, 25(2): 476-490. [28] Qin L, Williams JB, Tan T, et al. Deficiency of autism risk factor ASH1L in prefrontal cortex induces epigenetic aberrations and seizures[J]. Nat Commun, 2021, 12(1): 6589. [29] Tsetsos F, Yu D, Sul JH, et al. Synaptic processes and immune-related pathways implicated in Tourette syndrome[J]. Transl Psychiatry, 2021, 11(1): 56. [30] Dicks LMT. Gut Bacteria and neurotransmitters[J]. Microorganisms, 2022,10(9):1838. [31] Serrano-Castro P J, Rodríguez-Uranga JJ, Cabezudo-García P, et al. Cenobamate and clobazam combination as personalized medicine in autoimmune-associated epilepsy with anti-Gad65 antibodies[J]. Neurol Neuroimmunol Neuroinflamm,2023,10(6):e200151. [32] Liao Y, Fan L, Bin P, et al. GABA signaling enforces intestinal germinal center B cell differentiation[J]. Proc Natl Acad Sci U S A, 2022, 119(44): e2215921119. [33] Zhao H, Shi Y, Luo X, et al. The effect of fecal microbiota transplantation on a child with Tourette syndrome[J]. Case Rep Med, 2017, 2017: 6165239. [34] Xi W, Gao X, Zhao H, et al. Depicting the composition of gut microbiota in children with tic disorders: An exploratory study[J]. J Child Psychol Psychiatry, 2021, 62(10): 1246-1254. [35] Sanchez M, Fernández J, Martin M, et al. Purification and properties of two succinic semialdehyde dehydrogenases from Klebsiella pneumoniae[J]. Biochim Biophys Acta, 1989, 990(3): 225-231. [36] Strandwitz P, Kim KH, Terekhova D, et al. GABA-modulating bacteria of the human gut microbiota[J]. Nat Microbiol, 2019, 4(3): 396-403. [37] Yunes RA, Poluektovae U, Dyachkovam S, et al. GABA production and structure of gadB/gadC genes in Lactobacillus and Bifidobacterium strains from human microbiota[J]. Anaerobe, 2016, 42: 197-204. [38] Hartmann A. Clinical pharmacology of nondopaminergic drugs in Tourette syndrome[J]. Int Rev Neurobiol, 2013, 112: 351-372. [39] Awaad Y. Tics in Tourette syndrome: New treatment options[J]. J Child Neurol, 1999, 14(5): 316-319. [40] Singer HS, Wendlandt J, Krieger M, et al. Baclofen treatment in Tourette syndrome: A double-blind, placebo-controlled, crossover trial[J]. Neurology, 2001, 56(5): 599-604. [41] Giyyis AH, Leventhal DK, Fensterheim BA, et al. Selective inhibition of striatal fast-spiking interneurons causes dyskinesias[J]. J Neurosci, 2011, 31(44): 15727-15731. [42] 胡屹伟,巩利,李林文.肌苷和γ-氨基丁酸治疗抽动-秽语综合征疗效观察[J].山东医药,1995,39(7):12. Hu YW,Gong L,Li LW. Observation on the efficacy of inosine and gamma-aminobutyric acid in the treatment of Tourette′s syndrome[J]. Shandong Medicine,1995,39(7):12.(in Chinese) |